Literature DB >> 861885

Male pseudohermaphroditism: diagnosis in cell culture.

L Pinsky, M Kaufman, B Lambert, G Faucher, R Rosenfeld.   

Abstract

Testicular feminization is a classic form of complete male pseudohermaphroditism. The individuals have a normal XY karyotype but unambiguously female external genitalia. They have congenital complete insensitivity to androgen due to an X-linked mutation. In four patients (from tow families with several affected members) with the typical phenotype of testicular feminization, a severe deficit of specific androgen-binding activity was detected in cultured fibroblasts from labium majus skin. Measurement of this activity in genital skin fibroblasts improves the differential diagnosis in patients with complete or imcomplete male pseudohermaphroditism before puberty.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 861885      PMCID: PMC1879279     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  18 in total

1.  Persistent testicular delta5-isomerase-3beta-hydroxysteroid dehydrogenase (delta5-3beta-HSD) deficiency in the delta5-3beta-HSD form of congenital adrenal hyperplasia.

Authors:  G Schneider; M Genel; A M Bongiovanni; A S Goldman; R L Rosenfield
Journal:  J Clin Invest       Date:  1975-04       Impact factor: 14.808

2.  Locus on human X chromosome for dihydrotestosterone receptor and androgen insensitivity.

Authors:  W J Meyer; B R Migeon; C J Migeon
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Deficient 17 beta-hydroxysteroid oxidoreductase activity in testes from a male pseudohermaphrodite.

Authors:  D E Pittaway; R N Andersen; J R Givens
Journal:  J Clin Endocrinol Metab       Date:  1976-08       Impact factor: 5.958

5.  Steroid 17,20-desmolase deficiency: a new cause of male pseudohermaphroditism.

Authors:  M Zachmann; J A Völlmin; W Hamilton; A Prader
Journal:  Clin Endocrinol (Oxf)       Date:  1972-10       Impact factor: 3.478

6.  Preoperative detection of hidden testes.

Authors:  L S Levine; M I New
Journal:  Am J Dis Child       Date:  1971-02

7.  GM1 gangliosidosis in skin fibroblast culture: enzymatic differences between types 1 and 2 and observations on a third variant.

Authors:  L Pinsky; J Miller; B Shanfield; G Watters; L S Wolfe
Journal:  Am J Hum Genet       Date:  1974-09       Impact factor: 11.025

8.  Androgen insensitivity in man: evidence for genetic heterogeneity.

Authors:  J A Amrhein; W J Meyer; H W Jones; C J Migeon
Journal:  Proc Natl Acad Sci U S A       Date:  1976-03       Impact factor: 11.205

9.  Dihydrotestosterone binding by cultured human fibroblasts. Comparison of cells from control subjects and from patients with hereditary male pseudohermaphroditism due to androgen resistance.

Authors:  J E Griffin; K Punyashthiti; J D Wilson
Journal:  J Clin Invest       Date:  1976-05       Impact factor: 14.808

10.  Male pseudohermaphroditism presumably due to target organ unresponsiveness to androgens. Deficient 5alpha-dihydrotestosterone binding in cultured skin fibroblasts.

Authors:  M Kaufman; C Straisfeld; L Pinsky
Journal:  J Clin Invest       Date:  1976-08       Impact factor: 14.808

View more
  2 in total

1.  Replacement of arginine 773 by cysteine or histidine in the human androgen receptor causes complete androgen insensitivity with different receptor phenotypes.

Authors:  L Prior; S Bordet; M A Trifiro; A Mhatre; M Kaufman; L Pinsky; K Wrogeman; D D Belsham; F Pereira; C Greenberg
Journal:  Am J Hum Genet       Date:  1992-07       Impact factor: 11.025

2.  An exonic point mutation of the androgen receptor gene in a family with complete androgen insensitivity.

Authors:  T J Sai; S Seino; C S Chang; M Trifiro; L Pinsky; A Mhatre; M Kaufman; B Lambert; J Trapman; A O Brinkmann
Journal:  Am J Hum Genet       Date:  1990-06       Impact factor: 11.025

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.